Clinical use of subcutaneous G-CSF or GM-CSF in malignancy.
Disis
Mary L
ML
Center for Translational Medicine in Women's Health, University of Washington, Seattle, Washington 91809, USA. ndisis@u.washington.edu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D009503:Neutropenia / Q000188:drug therapy* / Q000209:etiology; D011092:Polyethylene Glycols; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; C081222:sargramostim; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000069585:Filgrastim